TUMOR-INTRINSIC GALECTIN-3 SUPPRESSES MELANOMA METASTASIS

Abstract: the present invention provides methods and composition for diagnosis, prognosis, prevention and/or treatment of cancers such as melanomas. the subject invention provides biomarkers (e.g., galectin-3 (gal-3)) and methods for assessing the severity of a cancer/tumor and for monitoring the progressing of a cancer/tumor. the compositions according to the subject invention regulate and alter melanoma signaling, growth, and survival. the subject invention also provides molecular mechanisms governing melanoma metastasis to identify candidate diagnostic or prognostic markers and develop novel therapeutic opportunities. further, the subject invention identifies the tumor-suppressive function of gal-3 in melanoma cells, emphasizing the negative crosstalk between gal-3 and nfat1 and its role in dictating melanoma metastasis.

Inventor(s): CHARLES J. DIMITROFF, NORHAN B. B. MOHAMMED

CPC Classification: A61K48/005 (Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy)

Search for rejections for patent application number 20250228968